Anti-obesity medications
Anti-obesity medications has been studied in 29 papers since 2016: 6 observational studies in people, 22 reviews; 12 in the past year. It has not reached trials in people. The newest paper, Nov 2, 2026: “Risk assessment and clinical strategies of muscle loss in weight loss therapy”.
InterventionPreclinical
29 papers study it28 findingsUpdated
3 new papers in 30 daysSee all 29 papers on anti-obesity medications
At a glance
The findings reach people, from one lab or study. 8 independent labs in 3 countries.
“every 5kg weight reduction mediated by AOMs was associated with the decreased risk of all-cause mortality in patients with overweight or obesity (RR = 0.73, 95%CI, 0.59 to 0.90)”
None of its findings points the other way.
- 8 independent labs in 3 countries
- Funders: National Institutes of Health and others
- 4 of 16 findings with company ties
- Humans6
- In silico1
Studies in people
3 studies gave anti-obesity medications to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on obesity-associated cancersRR = 1.03, 95% CI: 0.78 to 1.37 | Review of trials | 40,731 people pooledPatient cohorts | Obesity (Silver Spring, Md.), Nov 4, 2025 |
down: Lowers the risk of mortalityRR 0.73 (95% CI 0.59 to 0.90) no change: Has no effect on chronic kidney diseaseRR 0.86 (95% CI 0.58 to 1.27) no change: Has no effect on acute kidney injuryRR 0.98 (95% CI 0.78 to 1.21) | Review of trials | 140,384 people pooledPer 5 kg weight reduction mediated by AOMs vs placebo | ADA Scientific Sessions 2025 abstract, Jun 13, 2025 |
no change: Has no effect on obesity-associated cancersRR 0.99, 95% CI 0.86–1.13 | Review of trials | 90,900 people pooledBothIn patients with overweight or obesity | ADA Scientific Sessions 2025 abstract, Jun 13, 2025 |
What did studies of anti-obesity medications find?
13Studies of anti-obesity medications measured 13 outcomes; the most studied are body weight (6 studies), muscle mass (2) and obesity-associated cancers (2).
Body weight
downin humans3downin reviews2upin reviews1
6 studies
Body weight
downin humans3downin reviews2upin reviews1
Anti-obesity medications are linked with lower body weight in humans (before seeking bariatric surgery) (-13 kg (SD 10), -4.4 kg/m2 BMI).
“Among those who took AOMs before seeking bariatric surgery, average weight loss was 13 kg (SD 10) corresponding to a 4.4-kg/m2 decrease in BMI.”
Humansbefore seeking bariatric surgery
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
Anti-obesity medications decrease body weight in humans (neoadjuvant treatment before metabolic bariatric surgery).
“Neoadjuvant AOMs can induce clinically relevant weight loss”
Reviewneoadjuvant treatment before metabolic bariatric surgery
Polski przeglad chirurgiczny
Anti-obesity medications decrease body weight.
“Anti-obesity medications promote greater degrees of weight loss than lifestyle interventions alone.”
Review
Obesity reviews : an official journal of the International Association for the Study of Obesity
Anti-obesity medications decrease body weight (modest effects).
“While most approved weight loss medications have modest effects”
Review
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Anti-obesity medications improve body weight.
“All anti-obesity medications improve weight and metabolic parameters, with variable potency and effects depending on the specific drug.”
Review
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
EClinicalMedicine
Anti-obesity medications decrease body weight in humans (around 5% more than placebo).
“Pre-existing anti-obesity medications (AOMs) approved for long-term prescription use showed a weight reduction of around 5% more than placebo.”
Review
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
Journal of obesity & metabolic syndrome
Muscle mass
downin humans2OR 10
2 studies
Muscle mass
downin humans2OR 10
Anti-obesity medications decrease muscle mass in humans.
“Structured obesity management, including anti-obesity medications, also commonly leads to variable reductions in muscle mass with potential SO risk.”
Review
Clinical nutrition (Edinburgh, Scotland)
Anti-obesity medications decrease muscle mass in humans (weight loss) (~6 kg or 10%).
“This can equate to ∼6 kg or 10% of total lean mass after 12-18 mo, a loss comparable to a decade of human aging.”
Reviewweight loss12-18 mo
Current developments in nutrition
Obesity-associated cancers
no changein humans2RR 0.99–1.03
2 studies
Obesity-associated cancers
no changein humans2RR 0.99–1.03
Anti-obesity medications showed no clear effect on obesity-associated cancers in humans (RR = 1.03, 95% CI: 0.78 to 1.37).
“Compared with placebo, AOMs showed no association with the risk of overall obesity-related cancer (RR = 1.03, 95% CI: 0.78 to 1.37)”
Human trialn = 40,731
Obesity (Silver Spring, Md.)
Anti-obesity medications showed no clear effect on obesity-associated cancers in patients with overweight or obesity (RR 0.99, 95% CI 0.86–1.13).
“every 5 kg weight reduction mediated by AOMs was not associated with the overall risk of all 13 obesity-associated cancers in patients with overweight or obesity (RR = 0.99, 95%CI, 0.86 to 1.13)”
Human trialin patients with overweight or obesityevery 5 kg weight reductionn = 90,900
ADA Scientific Sessions 2025 abstract
Incident ocular outcomes
no changein humans1
1 study
Incident ocular outcomes
no changein humans1
Anti-obesity medications showed no clear effect on incident ocular outcomes in humans (randomized controlled trials).
“Randomized evidence identified no significant associations between any AOM and incident ocular outcomes or DR.”
Human trialrandomized controlled trials
Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis
Open Research (University of Surrey)
Mortality
downin humans1
1 study
Mortality
downin humans1
Anti-obesity medications decrease mortality in selected populations.
“lower all-cause mortality in selected populations”
Reviewin selected populations
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Journal of clinical medicine
Major cardiovascular events
downin humans1
1 study
Major cardiovascular events
downin humans1
Anti-obesity medications decrease major cardiovascular events in selected populations.
“AOMs reduce major cardiovascular events, slow kidney and liver disease progression, and lower all-cause mortality in selected populations”
Reviewin selected populations
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Journal of clinical medicine
Dementia
no changein humans1RR 1.02
1 study
Dementia
no changein humans1RR 1.02
Anti-obesity medications showed no clear effect on dementia in humans (randomized controlled trials versus placebo) (RR 1.02 (95% CI 0.41 to 2.54)).
“or dementia (RR = 1.02, 95% CI 0.41 to 2.54, P = 0.97) versus placebo”
Human trialrandomized controlled trials versus placebon = 35,924
Frontiers in pharmacology
Cognitive disorders
no changein humans1RR 0.94
1 study
Cognitive disorders
no changein humans1RR 0.94
Anti-obesity medications showed no clear effect on cognitive disorders in humans (randomized controlled trials versus placebo) (RR 0.94 (95% CI 0.39 to 2.25)).
“In RCTs, the use of AOMs was not associated with a lower risk of cognitive disorder (RR = 0.94, 95% CI 0.39 to 2.25, P = 0.88)”
Human trialrandomized controlled trials versus placebon = 35,924
Frontiers in pharmacology
Acute kidney injury
no changein humans1RR 0.98
1 study
Acute kidney injury
no changein humans1RR 0.98
Anti-obesity medications showed no clear effect on acute kidney injury in humans (weight reduction mediated by AOMs vs placebo) (RR 0.98 (95% CI 0.78 to 1.21)).
“or acute kidney injury (RR = 0.98, 95%CI, 0.78 to 1.21)”
Human trialweight reduction mediated by AOMs vs placebo
ADA Scientific Sessions 2025 abstract
Chronic kidney disease
no changein humans1RR 0.86
1 study
Chronic kidney disease
no changein humans1RR 0.86
Anti-obesity medications showed no clear effect on chronic kidney disease in humans (weight reduction mediated by AOMs vs placebo) (RR 0.86 (95% CI 0.58 to 1.27)).
“the weight reduction mediated by AOMs was not associated with the risk of chronic kidney disease (RR = 0.86, 95%CI, 0.58 to 1.27)”
Human trialweight reduction mediated by AOMs vs placebo
ADA Scientific Sessions 2025 abstract
All 13Fewer
What is anti-obesity medications linked with?
8Studies link anti-obesity medications with 8 measures, among them lifestyle interventions, mortality and colorectal cancer.
Lifestyle interventions
upin humans1
1 study
Lifestyle interventions
upin humans1
Anti-obesity medications are associated with lifestyle interventions in humans (adjunct to obesity management medications in Phase 3 trials).
“Lifestyle interventions have been core components in Phase 3 trials of FDA-approved OMMs.”
Reviewadjunct to obesity management medications in Phase 3 trials
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
Obesity science & practice
Mortality
downin humans1RR 0.73
1 study
Mortality
downin humans1RR 0.73
Anti-obesity medications lower the risk of mortality in humans (per 5 kg weight reduction mediated by AOMs vs placebo) (RR 0.73 (95% CI 0.59 to 0.90)).
“every 5kg weight reduction mediated by AOMs was associated with the decreased risk of all-cause mortality in patients with overweight or obesity (RR = 0.73, 95%CI, 0.59 to 0.90)”
Human trialper 5 kg weight reduction mediated by AOMs vs placebo
ADA Scientific Sessions 2025 abstract
Colorectal cancer
downin humans1
1 study
Colorectal cancer
downin humans1
Anti-obesity medications are linked with a lower risk of colorectal cancer in humans (aHR 0.82, 95% CI 0.71-0.96, p = 0.010).
“colorectal (aHR: 0.82; 95% CI: 0.71-0.96; p = 0.010), and advanced-stage colorectal cancers (aHR: 0.71; 95% CI: 0.54-0.91; p < 0.001).”
Humansfemales
Cancers
Breast cancer
downin humans1
1 study
Breast cancer
downin humans1
Anti-obesity medications are linked with a lower risk of breast cancer in humans (aHR 0.84, 95% CI 0.77-0.91, p < 0.001).
“Similar findings were observed in cancer-specific sites analysis, advanced-stage ORCs (aHR: 0.76; 95% CI: 0.65-0.89; p < 0.001), breast (aHR: 0.84; 95% CI: 0.77-0.91; p < 0.001)”
Humansfemales
Cancers
Obesity-related cancer
downin humans1
1 study
Obesity-related cancer
downin humans1
Anti-obesity medications are linked with a lower risk of obesity-related cancer in humans (aHR 0.78, 95% CI 0.73-0.84, p < 0.001).
“We found an inverse association between the use of AOMs and the risk of ORCs (aHR: 0.78; 95% CI: 0.73-0.84; p < 0.001).”
Humansfemales
Cancers
Gastrointestinal side effects
upin humans1
1 study
Gastrointestinal side effects
upin humans1
Anti-obesity medications are associated with gastrointestinal side effects in humans (reported in 32.2% of patients across studies).
“Gastrointestinal side effects were reported in 32.2% of patients across studies.”
Review
Clinical studies on anti-obesity medications in Arab countries
Saudi medical journal
Osteoarthritis
downin humans1
1 study
Osteoarthritis
downin humans1
Anti-obesity medications are linked with a lower risk of osteoarthritis in humans.
“The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users (hazard ratio (HR) = 073, 95% CI (0.67-0.79), p < 0.01).”
HumansAOM users compared with non-users, propensity-score matched and adjusted for comorbidities and sociodemographic factors6-month follow-up
The impact of approved anti-obesity medications on osteoarthritis
Expert opinion on pharmacotherapy
Periprocedural aspiration
upin reviews1
1 study
Periprocedural aspiration
upin reviews1
Anti-obesity medications raise the risk of periprocedural aspiration (periprocedural setting).
“altered gastrointestinal motility and risk for periprocedural aspiration”
Reviewperiprocedural setting
Alimentary pharmacology & therapeutics
Funding
3 grants since 2023National Institute of Diabetes and Digestive and Kidney Diseases$1.7MNational Heart, Lung, and Blood Institute$1.5M
National Institute of Diabetes and Digestive and Kidney DiseasesRush University Medical Center$942K2025–2028
National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of Kansas Medical Center$790K2025–2030
National Heart, Lung, and Blood InstituteHarvard Pilgrim Health Care$707K2023–2028